JOPIC
Journal of Pulmonology and Intensive Care

The JoPIC is an independent-unbiased, peer-reviewed, and open-access journal of current national and international issues and reviews for original clinical and experimental research, interesting case reports, surgical techniques, differential diagnoses, editorial opinions, letters to the editor, and educational papers in pulmonology, thoracic surgery, occupational diseases, allergology, and intensive care medicine.

eISSN: 2980-0803
Creative Commons CC BY-NC-ND 4.0 International License.
EndNote Style

Online Manuscript System

Index
Original Article
Effect of tocilizumab or anakinra use on prognosis in patients admission to intensive care due to COVID-19
Abstract
Aims: Anticytokine treatments may be beneficial in patients who do not benefit from glucocorticoid treatment, which is the first choice in systemic hyperinflammation cases caused by SARS-COV-2. Interleukin 6 receptor blocker tocilizumab and interleukin-1 receptor antagonist anakinra are anticytokines that have been granted off-label use permits by the Ministry of Health of the Republic of Turkiye. In this study, the effects of these two drugs on laboratory parameters used to evaluate mortality and clinical severity of the disease were investigated.
Methods: The files of patients who received tocilizumab and anakinra for the treatment of coronavirus disease-2019 between 01.07.2020-31.03.2022 in the Chest Diseases Intensive Care Unit of Adana City Training and Research Hospital were retrospectively reviewed.
Results: Mortality and mechanical ventilation requirement were found to be significantly lower in the tocilizumab group compared to the anakinra group (p=0.005, 0.01, respectively). C-reactive protein, pro-BNP and fibrinogen values continued to decrease in both groups. White blood count, D-dimer, neutrophil values increased in both groups. Unlike anakinra, tocilizumab decreased ferritin values and increased lymphocyte, platelet, INR, urea and aspartate transaminase, total bilirubin, red blood cell values (p=0.004, 0.035, 0.032, 0.09, p<0.001, p=0.002, p=0.006, p=0.008, respectively).
Conclusion: According to the results of this study, tocilizumab was found to be more successful than anakinra treatment in terms of mortality, need for mechanical ventilation and improvement of laboratory parameters, but liver and kidney functions should be monitored.

Keywords : Anakinra, COVID-19, intensive care, tocilizumab

Download Article


1. Zu ZY, Jiang MD, Xu PP, et al. Coronavirus Disease 2019 (COVID-19): a perspective from china.Radiology.2020;296:(2):E16-25.doi:10.1148/radiol.2020200490
2. Otsuka R, Seino KI. Macrophage activation syndrome and COVID-19.Inflamm Regener.2020;40:(19):2-6. doi:10.1186/s41232-020-00131-w
3. Hirano T, Murakami M. COVID-19: a new virus, but a familiar receptor and cytokine release syndrome.Immunity.2020;52(5):731-733.doi:10.1016/j.immuni.2020.04.003
4. Khani E, Shahrabi M, Rezaei H, Pourkarim F, Afsharirad H, Solduzian M. Current evidence on the use of anakinra in COVID-19. Int Immunopharmacol. 022;111:109075. doi:10.1016/j.intimp.2022.109075
5. 5. Antisitokin-Antiinflamatuar Tedaviler, Koagülopati Yönetimi, 07 Kasım 2020. Available from:https://covid19.saglik.gov.tr/TR-66341
6. 6. Zanza C, Romenskaya T, Manetti AC, et al. Cytokine storm in COVID-19: immunopathogenesis and therapy. Medicina. 2022;58(2): 144. doi:10.3390/medicina58020144
7. Salama C, Han J, Yau L, et al. Tocilizumab in patients hospitalized with COVID-19 pneumonia.Engl J Med.2021;384(1):20-30.doi:10.1056/NEJMoa2030340
8. Dahms K, Mikolajewska A, Ansems K, Metzendorf MI, Benstoem C, Stegemann M. Anakinra for the treatment of COVID-19 patients: a systematic review and meta-analysis.Eur J Med Res. 2023;28(1):100. doi:10.1186/s40001-023-01072-z
9. Küçükşahin O, Erden A, Karakaş Ö, et al. Comparison of anakinra and tocilizumab in management of severe COVID-19: a retrospective cohort study. Turkish J Med Sci. 2022;52(5):1486-1494. doi:10.55730/1300-0144. 5487
10. Akın A, Safi Y, Yılmaz TS. COVID-19’a bağlı sitokin fırtınasında anakinra ve tosilizumab tedavilerinin karşılaştırılması.Sağlık Bil Değer. 2023;13(1):73-79.doi:10.33631/sabd.1119769
11. Zantah M, Castillo ED, Gangemi AJ, et al. Anakinra and intravenous IgG versus tocilizumab in the treatment of COVID-19 pneumonia.MedRxiv. 2020:9.doi:10.1101/2020.09.11.20192401
12. Arcani R, Correard F, Suchon P, et al. Tocilizumab versus anakinra in COVID-19: results from propensity score matching.Front Immunol. 2023;26(14):1185716. doi:10.3389/fimmu.2023.1185716
13. Acat M, Çavdar Ö, Tezce A, Acat BP. Comparison of tocilizumab and anakinra in the treatment of COVID-19: a single-center experience.Duzce Med J.2022;24(2):116-120.doi:10.18678/dtfd.1084026
14. Ozkan F, Sari S. Comparison of anakinra and tocilizumab in anticytokine therapy in the treatment of coronavirus disease-2019.Indian J Crit Care Med.2022;26(10):1091-1098.doi:10.5005/jp-journals- 10071-24320
15. De la Calle C, Lopez-Medrano F, Pablos JL, et al. Effectiveness of anakinra for tocilizumab-refractory severe COVID-19. A single centre retrospective comparative study.Int J Infect Dis.2021;105:319-325. doi: 10.1016/j.ijid.2021.02.041
16. Yao XH, Li TY,He ZC, et al. A pathological report of three COVID-19 cases by minimally invasive autopsies.<strong></strong>Chinese J Pathol.2020;49(5):411-417. doi:10.3760/cma.j.cn112151-20200312-00193
17. Jamilloux Y, Henry T, Belot A, et al. Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions. Autoimmunity Reviews.2020;19(7):102567. doi:10.1016/j.autrev.2020.102567
18. Özdemir L, Özdemir B, Çelik MM, Urfalı S, Akgündüz B, Gegin S. COVID-19 pnömonisi nedeni ile tosilizumab uygulanan hastaların özellikleri. İzmir Göğüs Hastanesi Dergisi.2024;38(1):95-107.
19. Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome.Lancet Respir Med. 2020;8(4):420-422. doi:10.1016/S2213-2600(20)30076-X
20. Vural DG, Usta B, Emre Daştan MS, et al. COVID-19 tanılı hastalarda interlökin-6, C-reaktif protein ve prokalsitonin düzeylerinin hastalığın prognozuna etkisinin değerlendirilmesi.Turk J Immunol. 2022;10(3): 149-154. doi:10.4274/tji.galenos.2022.70298
21. Aljuhani O, Al Sulaiman K, Korayem GB, et al. The association between tocilizumab therapy and the development of thrombosis in critically ill patients with COVID-19: a multicenter, cohort study.Sci Rep. 2024; 14(1):3037. doi:10.1038/s41598-024-53087-z
22. Saruhan R, Uzundere O. Efficacy of tocilizumab in critically ill COVID-19 patients followed in the intensive care unit.Turk J of Intensive Care. 2024;22(3):197-206. doi:10.4274/tybd.galenos.2023.28199
23. Majure DT, Gruberg L, Saba SG, et al. Usefulness of elevated troponin to predict death in patients with COVID-19 and myocardial injury.Am J Cardiol. 2021;138:100-106. doi:10.1016/j. amjcard.2020.09.060
24. Wang X, Tang G, Liu Y, et al. The role of IL-6 in coronavirus, especially in COVID-19. Front Pharmacol. 2022;13:1033674.doi:10.3389/fphar. 2022.1033674
25. Langer-Gould A, Smith JB, Gonzales EG, et al. Early identification of COVID-19 cytokine storm and treatment with anakinra or tocilizumab.Int J Infect Dis.2020;99:291-297.doi:10.1016/j.ijid.2020.07.081
26. Available from:https://clinicaltrials.gov. 06.26.2025
Article available in :
Volume 3, Issue 4, 2025
Page : 89-93
https://doi.org/10.51271/JOPIC-0066
Article Information
Received : 04 Tem 2025
Accepted : 26 Ağu 2025
Published : 29 Kas 2025
Corresponding Author :

Elif Karabacak: Department of Pharmacology, Faculty of Pharmacy, Düzce University, Düzce, Turkiye

[email protected]
Citation : Kubat H, Karabacak E, Aybal E, Erçen Diken Ö. Effect of tocilizumab or anakinra use on prognosis in patients admission to intensive care due to COVID-19. J Pulmonol Intens Care. 2025;3(4):89-93.

Read: 53
Download : 31
Cited: 0
_Footer